Hayward G et al., 2024-04: The UK PRINCIPLE platform trial randomized 2157 community patients to ivermectin 300-400 micrograms/kg daily for three days; recovery was marginally faster but below the prespecified threshold for a meaningful effect, and hospitalisations and deaths were unchanged.
Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes.
Hayward G et al., 2024-04: The UK PRINCIPLE platform trial randomized 2157 community patients to ivermectin 300-400 micrograms/kg daily for three days; recovery was marginally faster but below the prespecified threshold for a meaningful effect, and hospitalisations and deaths were unchanged. Multicentre, open-label, multi-arm adaptive platform randomized controlled trial, United Kingdom; primary analysis 8811 SARS-CoV-2 positive participants randomized to ivermectin (n=2157), usual care (n=3256) and other treatments (n=3398), June 2021-July 2022; ivermectin target 300-400 micrograms/kg per dose once daily for 3 days. Time to recovery HR 1.15 (95% Bayesian credible interval 1.07-1.23), median decrease 2.06 days, but posterior probability of a prespecified meaningful effect (HR>=1.2) only 0.192; hospitalisation/death OR 1.02 (0.63-1.62). Funded by UKRI/NIHR (MC_PC_19079); ISRCTN86534580. Competing-interest statement lists grants from the University of Oxford/NIHR for statistical design. Study type: randomized trial.
